products

CAS 1009119-64-5 Active Pharmaceutical Ingredients Powder 99% Purity Daclatasvir

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 1009119-64-5
Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 1009119-64-5 Apparence: White Powder
Purity: 99% Other Name: BMS-790052; EBP 883; Daclatasvir;
Grade: Pharma Grade Usage: Treat A Certain Type Of Chronic Hepatitis C
High Light:

pharmaceutical raw chemical

,

api raw material


Product Description

Daclatasvir BMS-790052 Hepatitis C Treatment Drugs CAS 1009119-64-5 White Powder
 
Quick detail


Daclatasvir
CAS No.: 1009119-64-5
Synonyms:

Carbamic acid, N,​N'-​[[1,​1'-​biphenyl]​-​4,​4'-​diylbis[1H-​imidazole-​5,​2-​diyl-​(2S)​-​2,​1-​pyrrolidinediyl[(1S)​-​1-​(1-​methylethyl)​-​2-​oxo-​2,​1-​ethanediyl]​]​]​bis-​, C,​C'-​dimethyl ester;
N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester;
BMS-790052; EBP 883; Daclatasvir;

Formula: C40H50N8O6
Exact Mass: 738.38500
Molecular Weight: 738.87500
PSA: 174.64000
LogP: 6.87960

 
Daclatasvir Description


Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. It is not known if daclatasvir prevents the spread of hepatitis C to other people.
 
CAS 1009119-64-5 Active Pharmaceutical Ingredients Powder 99% Purity Daclatasvir 0
 
Daclatasvir Uses


Uses 1

Treatment for the ALLY-3 Clinical Trial

Uses 2 Treatment for Hepatitis C Genotype 3
Uses 3 Treatment for Bristol-Myers Squibb’s Patient Support Connect Program
Uses 4
Treatment for Bristol-Myers Squibb in HCV

 
Who can use daclatasvir


Daclatasvir is indicated for use by adults with chronic hepatitis C, meaning infection lasting more than six months. It is approved for people with HCV genotype 1, 2, 3 or 4. Genotype 1 is the most common type in Europe and considered the hardest to treat.
Daclatasvir can be used by people being treated for hepatitis C for the first time (known as 'treatment-naive') and for retreatment of people who were not cured with previous interferon-based therapy (known as 'treatment-experienced').
 
The safety and effectiveness of daclatasvir for people with HIV and HCV co-infection has not yet been determined, but this is now being tested. Studies have shown that daclatasvir does not have problematic interactions with most widely used HIV drugs. People with HIV and HCV co-infection who want to take daclatasvir should do so under the care of a doctor who has experience treating both HIV and HCV.
 
Daclatasvir can be used by people with all stages of compensated liver disease including cirrhosis. However, it works better for people with less advanced liver damage. Daclatasvir is now being tested for people with chronic hepatitis C who are awaiting or have received liver transplants.
 
How is daclatasvir taken


Daclatasvir is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food. It must be used in combination with other hepatitis C medications and is not effective if taken alone. Treatment should be managed by a doctor who has experience treating hepatitis C.
 

 

 
Combined with:
 

 
Length of treatment
 

Genotype 1
 

Daclatasvir & sofosbuvir

12 weeks (no cirrhosis)
24 weeks (with cirrhosis)

Genotype 1
 

Daclatasvir & sofosbuvir & ribavirin

12 weeks (post-liver transplant, no cirrhosis)
12 weeks (with cirrhosis A or B)
24 weeks (with decompensated cirrhosis)

Genotype 2
 

Daclatasvir & sofosbuvir Evidence lacking to make a recommendation on duration; at least 12 weeks.

Genotype 3
 

Daclatasvir & sofosbuvir 12 weeks (no cirrhosis)

Genotype 3
 

Daclatasvir & sofosbuvir & ribavirin

12 weeks (post-transplant, no cirrhosis)
24 weeks (with cirrhosis)

Genotype 4
 

Daclatasvir & sofosbuvir

12 weeks (no cirrhosis)
24 weeks (with cirrhosis)

Genotype 4
 

Daclatasvir & sofosbuvir & ribavirin

12 weeks (post-transplant or with cirrhosis A or B)
24 weeks (with decompensated cirrhosis)

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156